Demographic and baseline clinical characteristics in the overall population
| Characteristic . | Overall N = 103 . |
|---|---|
| Age, median (range), y | 72 (20-87) |
| Age group, y, n (%) | |
| <65 | 28 (27.2) |
| 65 to <75 | 39 (37.9) |
| ≥75 | 36 (35.0) |
| Sex at birth, n (%) | |
| Male | 57 (55.3) |
| Female | 46 (44.7) |
| Race, n (%) | |
| White | 78 (75.7) |
| Black or African American | 4 (3.9) |
| Asian | 4 (3.9) |
| Other | 1 (1.0) |
| Not reported | 16 (15.5) |
| Ethnicity,∗ n (%) | |
| Hispanic or Latino | 3 (2.9) |
| Not Hispanic or Latino | 22 (21.4) |
| Not reported | 3 (2.9) |
| Missing | 75 (72.8) |
| Region, n (%) | |
| Europe | 74 (71.8) |
| North America | 28 (27.2) |
| Australia | 1 (1.0) |
| ECOG performance status, n (%) | |
| 0 | 33 (32.0) |
| 1 | 57 (55.3) |
| 2 | 13 (12.6) |
| IPI, n (%) | |
| <3 | 38 (36.9) |
| ≥3 | 65 (63.1) |
| Bulky disease by IRC assessment,† n (%) | |
| <7 cm (nonbulky disease) | 62 (60.2) |
| 7 to 10 cm | 18 (17.5) |
| >10 cm | 20 (19.4) |
| DLBCL type,‡ n (%) | |
| De novo | 75 (72.8) |
| Transformed | 24 (23.3) |
| Double- or triple-hit lymphoma (MYC and BCL2 and/or BCL6 rearrangement) by central laboratory,§ n/n (%) | 6/58 (10.3) |
| DLBCL cell of origin,|| n (%) | |
| Activated B cell/non–germinal center B cell | 43 (41.7) |
| Germinal center B cell | 41 (39.8) |
| Unknown | 19 (18.4) |
| Ann Arbor stage, n (%) | |
| I or II | 22 (21.4) |
| III | 18 (17.5) |
| IV | 63 (61.2) |
| Time from initial diagnosis to first dose of epcoritamab, median (range), mo | 13.2 (0.6-177.7) |
| Time from end of last therapy to first dose of epcoritamab, median (range), mo | 4.6 (0.6-98.9) |
| Prior lines of antilymphoma therapy, median (range) | 2 (1-6) |
| Prior lines of antilymphoma therapy, n (%) | |
| 1 | 39 (37.9) |
| 2 | 27 (26.2) |
| ≥3 | 37 (35.9) |
| Primary refractory disease,¶,# n (%) | 54 (52.4) |
| Refractory to last systemic therapy,# n (%) | 72 (69.9) |
| Refractory to ≥2 consecutive lines of therapy,# n (%) | 38 (36.9) |
| Prior ASCT, n (%) | 10 (9.7) |
| Relapsed ≤12 mo after ASCT, n/n (%) | 5/10 (50.0) |
| Prior CAR T-cell therapy, n (%) | 29 (28.2) |
| Characteristic . | Overall N = 103 . |
|---|---|
| Age, median (range), y | 72 (20-87) |
| Age group, y, n (%) | |
| <65 | 28 (27.2) |
| 65 to <75 | 39 (37.9) |
| ≥75 | 36 (35.0) |
| Sex at birth, n (%) | |
| Male | 57 (55.3) |
| Female | 46 (44.7) |
| Race, n (%) | |
| White | 78 (75.7) |
| Black or African American | 4 (3.9) |
| Asian | 4 (3.9) |
| Other | 1 (1.0) |
| Not reported | 16 (15.5) |
| Ethnicity,∗ n (%) | |
| Hispanic or Latino | 3 (2.9) |
| Not Hispanic or Latino | 22 (21.4) |
| Not reported | 3 (2.9) |
| Missing | 75 (72.8) |
| Region, n (%) | |
| Europe | 74 (71.8) |
| North America | 28 (27.2) |
| Australia | 1 (1.0) |
| ECOG performance status, n (%) | |
| 0 | 33 (32.0) |
| 1 | 57 (55.3) |
| 2 | 13 (12.6) |
| IPI, n (%) | |
| <3 | 38 (36.9) |
| ≥3 | 65 (63.1) |
| Bulky disease by IRC assessment,† n (%) | |
| <7 cm (nonbulky disease) | 62 (60.2) |
| 7 to 10 cm | 18 (17.5) |
| >10 cm | 20 (19.4) |
| DLBCL type,‡ n (%) | |
| De novo | 75 (72.8) |
| Transformed | 24 (23.3) |
| Double- or triple-hit lymphoma (MYC and BCL2 and/or BCL6 rearrangement) by central laboratory,§ n/n (%) | 6/58 (10.3) |
| DLBCL cell of origin,|| n (%) | |
| Activated B cell/non–germinal center B cell | 43 (41.7) |
| Germinal center B cell | 41 (39.8) |
| Unknown | 19 (18.4) |
| Ann Arbor stage, n (%) | |
| I or II | 22 (21.4) |
| III | 18 (17.5) |
| IV | 63 (61.2) |
| Time from initial diagnosis to first dose of epcoritamab, median (range), mo | 13.2 (0.6-177.7) |
| Time from end of last therapy to first dose of epcoritamab, median (range), mo | 4.6 (0.6-98.9) |
| Prior lines of antilymphoma therapy, median (range) | 2 (1-6) |
| Prior lines of antilymphoma therapy, n (%) | |
| 1 | 39 (37.9) |
| 2 | 27 (26.2) |
| ≥3 | 37 (35.9) |
| Primary refractory disease,¶,# n (%) | 54 (52.4) |
| Refractory to last systemic therapy,# n (%) | 72 (69.9) |
| Refractory to ≥2 consecutive lines of therapy,# n (%) | 38 (36.9) |
| Prior ASCT, n (%) | 10 (9.7) |
| Relapsed ≤12 mo after ASCT, n/n (%) | 5/10 (50.0) |
| Prior CAR T-cell therapy, n (%) | 29 (28.2) |
ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index.
Ethnicity was not reported for patients enrolled outside of the United States.
A total of 12 patients had bulky disease of >10 cm by investigator assessment. Bulky disease status by IRC was missing for 3 patients.
De novo vs transformed status was missing for 4 patients.
MYC and BCL2 and/or BCL6 rearrangement by central laboratory was not assessed in 45 patients.
DLBCL cell of origin was determined by local laboratory.
Primary refractory disease is defined as disease that is refractory to first-line antilymphoma therapy.
Refractory disease is defined as disease progression or stable disease as best overall response during therapy or progression within 6 months of completion of therapy.